Sony Interactive Entertainment Inc. et al. v. Resonant Systems, Inc.

Sarepta Therapeutics, Inc et al.vsThe Trustees of the University of Pennsylvania et al.

The Board issued a Final Written Decision upholding the validity of claim 8 in this gene therapy IPR. The decision found that Petitioner failed to demonstrate sufficient motivation or reasonable expectation of success to combine prior art references under 35 U.S.C. § 103(a).

Samsung Electronics America, Inc. et al.vsCobblestone Wireless LLC

Samsung Electronics America filed a petition challenging the validity of Cobblestone Wireless's '802 patent, asserting that its multi-carrier transmission claims are obvious in light of mid-2000s prior art. The petitioner argues that established technologies like Suzuki and Fernandez render the claimed methods predictable modifications to known systems.

Bruker Spatial Biology, Inc.vs10x Genomics, Inc. et al.

Nanostring Technologies challenges U.S. Patent No. 11,542,554 in a PTAB Petition, arguing that numerous claims are obvious over combinations of prior art references like Zhuang, Cai, and Shen. The petitioner asserts the core technology for 3D positional information in nucleic acid imaging was already well-known in biological imaging.

Dr. Squatch, LLCvsThe Procter & Gamble Company

Dr. Squatch challenged Procter & Gamble's deodorant patent (10,966,915) in an IPR petition, arguing that the claimed natural ingredient compositions are anticipated or obvious over existing prior art. The petitioner asserts that various combinations of references like Lesniak and Native render the claims invalid under 35 U.S.C. §§ 102 and 103.

NEURENT MEDICAL INC. et al.vsThe Foundry, LLC et al.

NEURENT MEDICAL INC. successfully petitioned PTAB for institution of IPR against THE FOUNDRY, LLC's nasal cavity treatment patent (11679077). The Board found sufficient evidence across multiple grounds of anticipation and obviousness to proceed to trial.